Docusign Envelope ID: 8630B41E-7293-46EC-A720-C134649B34D7

Ambu Nordic A/S

Baltorpbakken 13, 2750 Ballerup,

CVR no. 40 31 14 08

Annual report 2023/24

Approved at the Company's annual general meeting on 17 February 2025

Chairman:

Signed by:
Henrik Skak Bender
D5C6821B067E4A9...

Henrik Skak Bender

Docusign Envelope ID: 8630B41E-7293-46EC-A720-C134649B34D7

Contents

Company information **2**

Statement by Management **3**

Management's review **4**

Financial statements 1 October 2023 – 30 September 2024 **5**
Income statement 5
Balance sheet 6
Statement of changes in equity 7
Notes 8

Docusign Envelope ID: 8630B41E-7293-46EC-A720-C134649B34D7

Company information

Company
Ambu Nordic A/S
Baltorpbakken 13
2750 Ballerup
CVR no. 40 31 14 08

Home: Ballerup

Executive Board:
Sjur Teksle Nøland

Board of Directors:
Henrik Skak Bender (chairman)
Sjur Teksle Nøland
Anita Krarup Frederiksen

Docusign Envelope ID: 8630B41E-7293-46EC-A720-C134649B34D7

Statement by Management

The Board of Directors and the Executive Board have today discussed and approved the annual report of Ambu Nordic A/S for the financial year 1 October 2023 – 30 September 2024.

The annual report has been prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the financial position of the Company at 30 September 2024 and of the results of its operations for the financial year 1 October 2023 – 30 September 2024.

Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.

We recommend that the annual report be approved at the annual general meeting.

Further, we decided that the annual report for the financial year 2023/24 will not be audited. The Board of Directors and the Executive Board consider the terms to deselect auditing to be fulfilled.

Ballerup, 17 February 2025

Executive Board:

DocuSigned by:
Sjur Nøland
EA6F3657AD54489...
Sjur Teksle Nøland

Board of Directors:

Signed by:
Henrik Skak Bender
D5C6821B067E4A9...
Henrik Skak Bender
Chairman

DocuSigned by:
Sjur Nøland
EA6F3657AD54489...
Sjur Teksle Nøland

DocuSigned by:
Anita Krarup Frederiksen
D87C147322AB4FE...
Anita Krarup Frederiksen

Docusign Envelope ID: 8630B41E-7293-46EC-A720-C134649B34D7

Management's review

Principal activities

The principal activity of the Company is to conduct trade within the medico industry both nationally and abroad. The Company can as a shareholder or as a stakeholder within investment, loan and credit, have interest in other companies with same purpose as indicated above.

Docusign Envelope ID: 8630B41E-7293-46EC-A720-C134649B34D7

Financial statements 1 October 2023 – 30 September 2024

Income statement

Note	DKK	2023/24	2022/23
	Other external expenses	-1,500	-1,375
	Gross Profit/loss	**-1,500**	**-1,375**
	Financial expenses	-520	-412
	Profit/loss before tax	**-2,020**	**-1,787**
3	Tax for the year	0	0
	Profit for the year	**-2,020**	**-1,787**
	Proposed distribution of result		
	Transferred to equity reserves	-2,020	-1,787
		-2,020	**-1,787**

Docusign Envelope ID: 8630B41E-7293-46EC-A720-C134649B34D7

Financial statements 1 October 2023 – 30 September 2024

Balance sheet

Note	DKK	2023/24	2022/23
	ASSETS		
	Non-current assets		
4	Other securities and equity investments	1,253	1,773
	Total non-current assets	**1,253**	**1,773**
	Current assets		
	Unpaid share capital	376,275	377,525
	Total current assets	**376,275**	**377,525**
	Total assets	**377,528**	**379,298**
	EQUITY AND LIABILITIES		
	Equity		
	Share capital	400,000	400,000
	Unpaid share capital	376,275	377,525
	Retained earnings	-405,122	-404,352
	Total equity	**371,153**	**373,173**
	Current liabilities		
	Trade payables	1,375	1,125
	Payables to group entities	5,000	5,000
	Total current liabilities	**6,375**	**6,125**
	Total equity and liabilities	**377,528**	**379,298**

1 Accounting policies
6 Contractual obligations and contingencies, etc.
7 Related parties
8 Consolidated financial statements

Docusign Envelope ID: 8630B41E-7293-46EC-A720-C134649B34D7

Financial statements 1 October 2023 – 30 September 2024

Statement of changes in equity

DKK	Share capital	Reserve for unpaid Share capital	Retained earnings	Total
Equity at 1 October	400,000	377,525	-404,352	373,173
Proposed distribution of result for the year	0	-1,250	-770	-2,020
Equity at 30 September	400,000	376,275	-405,122	371,153

Docusign Envelope ID: 8630B41E-7293-46EC-A720-C134649B34D7

Financial statements 1 October 2023 – 30 September 2024

Notes

1 Accounting policies

The annual report of Ambu Nordic A/S for 2023/24 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class B entities and elective choice of certain provisions applying to reporting class C entities.

Pursuant to section 112(1) of the Danish Financial Statements Act, the Company has not prepared consolidated financial statements.

Income statement

Other external expenses

Other external expenses comprise expenses relating to administration.

Financial expenses

Financial expenses consist of impairment of other securities and equity investments.

Tax for the year

Tax for the year comprises current tax for the year and changes in deferred tax. The tax expense relating to the profit/loss for the year is recognised in the income statement, and the tax expense relating to amounts recognised directly in equity is recognised directly in equity.

Balance sheet

Financial assets

Other securities and equity investments are measured at cost. Cost includes the consideration measured at fair value plus direct acquisition costs. In case of indication of impairment, an impairment test is conducted. Equity investments are written down to the lower of the carrying amount and the recoverable amount.

Docusign Envelope ID: 8630B41E-7293-46EC-A720-C134649B34D7

Financial statements 1 October 2023 – 30 September 2024

Notes

1 Accounting policies (continued)

Receivables

Receivables are measured at amortised cost which usually corresponds to nominal value. The value is reduced by write-down to meet expected losses.

Equity

Income tax and deferred tax

Current tax payables and receivables are recognised in the balance sheet as tax computed on the taxable income for the year, adjusted for tax on prior-year taxable income and tax paid on account.

Deferred tax is measured using the balance sheet liability method on all temporary differences between the carrying amount and the tax base of assets and liabilities. Where alternative tax rules can be applied to determine the tax base, deferred tax is measured based on the intended use of the asset or settlement of the liability, respectively.

Deferred tax assets, including the tax base of tax loss carryforwards, are measured at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set-off against deferred tax liabilities within the same legal tax entity. Any deferred net assets are measured at net realisable values.

Deferred tax is measured according to the tax rules and at the tax rates applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Changes in deferred tax due to changes in tax rates are recognised in the income statement.

Liabilities

Financial liabilities comprising trade payables are recognised at the date of borrowing at cost, corresponding to the proceeds received less transaction costs paid. In subsequent periods, financial liabilities are measured at amortised cost.

Other liabilities are measured at net realisable value.

Docusign Envelope ID: 8630B41E-7293-46EC-A720-C134649B34D7

Financial statements 1 October 2023 – 30 September 2024

Notes

2 **Staff costs**

The company does not have employees

3 **Tax for the year**

DKK

	2032/24	**2022/2023**
Deferred tax adjustment for the year	0	0
	0	0

4 **Other securities and equity investments**

DKK

	2023/24	**2022/2023**
Cost at 1 October	5,000	5,000
Cost at 30 September	**5,000**	**5,000**
Impairment losses for the year	-3,747	-3,227
Impairment losses at 30 September	-3,747	-3,227
Carrying amount at 30 September	**1,253**	**1,773**

5 Share capital

DKK	**2024**
The share capital comprises:	
Class A shares, 400.000 shares of nom. DKK 1 each	400,000
	400,000

Docusign Envelope ID: 8630B41E-7293-46EC-A720-C134649B34D7

Financial statements 1 October 2023 – 30 September 2024

Notes

6 Contractual obligations and contingencies, etc.

Contingent liabilities

The Company is jointly taxed with Ambu A/S as administration company. The Company has unlimited joint and several liability for payment of Danish corporation taxes. The jointly taxed entities' total known net liability in respect of corporation taxes payable is reported in the annual report for Ambu A/S. Any subsequent corrections of the income subject to joint taxation may entail that the Company's liability will increase.

7 Related parties

Ambu Nordic A/S' related parties comprise the following:

Control

Ambu A/S, Baltorpbakken 13, 2750 Ballerup, which exercises control.

Other related parties

Ambu Rusland Holding ApS

Related party transactions

In 2023/24, the Company had related party transactions with its parent company Ambu A/S. Such transactions, which accounted for less than 1% of the Parent Company's revenue, were carried out on terms identical to those applied in transactions with unrelated parties.

8 Consolidated financial statements

The Company is included in the consolidated financial statements of Ambu A/S, Baltorpbakken 13, 2750 Ballerup. The consolidated financial statements can be obtained from the website of the parent company.